You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Your guide to maintenance treatment with Zejula (niraparib)

Image showing a graphic of 2 people talking

The information on this site is intended to support the care you receive from your healthcare team. It is important that you speak with them if you have any questions about your treatment or have any side effects.

Here, you will find some resources to help guide your maintenance treatment with Zejula, and help you feel comfortable and hopefully, more in control of your care.

Your guide to maintenance treatment with Zejula

The patient information booklet includes information on some of the questions you may have about Zejula and aims to help support you on your treatment journey.

Please click here to download the Zejula patient information booklet.

If you have any questions about your maintenance treatment, please speak to a member of your healthcare team who will be able to help you further.

Zejula is a registered trademark of the GlaxoSmithKline group of companies.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed on this website or in the product package leaflet. You can also report side effects directly to HPRA Pharmacovigilance on their website: By reporting side effects, you can help provide more information on the safety of this medicine.